Pediatric dyslipidemias: Prescription medication efficacy and safety

Journal of Clinical Lipidology

Volumn 2, Issue 3, 2008, Pages 189-201

  Browne, Barry ^a   Vasquez, Susie ^a  

^a TEXAS A M COLLEGE OF MEDICINE   (United States)

Author keywords

Bile acid sequestrants; Dyslipidemia; Ezetimibe; Familial hypercholesterolemia; Fibrates; HMG CoA reductase inhibitors; Niacin; Pediatrics; Pharmacotherapy; Statins

Indexed keywords

AMIODARONE; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; BILE ACID SEQUESTRANT; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; CYCLOSPORIN; DIGOXIN; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOFIBRA GATE; LOVAZA; MEVINOLIN; NICOTINIC ACID; OMEGA 3 FATTY ACID; ORAL CONTRACEPTIVE AGENT; PHENYTOIN; PLACEBO; PRAVASTATIN; PREVALITE; PROTEINASE INHIBITOR; ROSUVASTATIN; SIMVASTATIN; THYROXINE; TRIGLIDE; UNINDEXED DRUG; VERAPAMIL; WARFARIN;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; BLEEDING; BLOATING; CHILDHOOD DISEASE; CHOLELITHIASIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DIET THERAPY; DISEASE SEVERITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG COMPETITION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG INHIBITION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; DYSPEPSIA; EPISTAXIS; FAMILIAL HYPERCHOLESTEROLEMIA; FLATULENCE; FLU LIKE SYNDROME; FLUSHING; FOOD; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; GRAPEFRUIT JUICE; HUMAN; HYPERCHLOREMIC ACIDOSIS; HYPERGLYCEMIA; HYPERHOMOCYSTEINEMIA; HYPERURICEMIA; INDIGESTION; INFECTION; INFLUENZA; INFORMATION RETRIEVAL; LIVER DYSFUNCTION; LONG TERM CARE; LOW DRUG DOSE; LOW FAT DIET; MEDLINE; MONOTHERAPY; MUSCLE WEAKNESS; MYALGIA; MYOGLOBINURIA; MYOPATHY; NAUSEA; PATIENT COMPLIANCE; PHARYNGITIS; PRIORITY JOURNAL; PRURITUS; REVIEW; RHABDOMYOLYSIS; RISK BENEFIT ANALYSIS; SIDE EFFECT; STOMACH PAIN; TASTE DISORDER; TOXIC HEPATITIS; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VASCULAR DISEASE; VITAMIN BLOOD LEVEL; VOMITING;

EID: 43549083890     PISSN: 19332874     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacl.2008.04.008     Document Type: Review

References (76)

1. National Cholesterol Education Program. Highlights of the report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics 89 (1992) 495-501
2. McCrindle B.W., Urbina E.M., Dennison B.A., et al. Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. Circulation 115 (2007) 1948-1967
3. American Academy of Pediatrics, and Committee on Nutrition. Cholesterol in childhood. Pediatrics 101 (1998) 141-147
4. Kavey R.W., Allada V., Daniels S.R., et al. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation 114 (2006) 2710-2738
5. Sibley C., and Stone N.J. Familial hypercholesterolemia: a challenge of diagnosis and therapy. Cleve Clin J Med 73 (2006) 57-64
6. Mahley R.W., and Bersot T.P. Drug therapy for hypercholesterolemia and dyslipidemia. In: Brunton L.L. (Ed). Goodman and Gilman's The Pharmacologic Basis of Therapeutics. 11th ed. (2006), McGraw-Hill, New York 933-966
7. Haney E.M., Huffman L.H., Bougatsos C., Freeman M., Steiner R.D., and Nelson H.D. Screening and treatment for lipid disorders in children and adolescents: systematic evidence review for the US Preventive Services Task Force. Pediatrics 120 (2007) e189-e214
8. Clauss S.B., Holmes K.W., Hopkins P., et al. Efficacy and safety of lovastatin therapy in adolescent girls with heterozygous familial hypercholesterolemia. Pediatrics 116 (2005) 682-688
9. de Jongh S., Ose L., Szamosi T., et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial with simvastatin. Circulation 106 (2002) 2231-2237
10. McCrindle B.W., Ose L., and Marais A.D. Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial. J Pediatr 143 (2003) 74-80
11. Wiegman A., Hutten B.A., de Groot E., et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA 292 (2004) 331-337
12. National Institutes of Health. PLUTO: Pediatric Lipid-redUction Trial of rOsuvastatin. http://www.clinicaltrials.gov/ct/show/NCT00355615 Accessed December 2007
13. McCrindle B.W., Helden E., Cullen-Dean G., and Conner W.T. A randomized crossover trial of combination pharmacologic therapy in children with familial hyperlipidemia. Pediatr Res 51 (2002) 715-721
14. Atorvastatin [product monograph] (2007), Pfizer, New York
15. Simvastatin [product monograph] (2007), Merck & Co, Whitehouse Station, NJ
16. McKenney J.M., Davidson M.H., Jacobson T.A., Guyton J.R., and National Lipid Association Statin Safety Assessment Task Force. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol 97 suppl (2006) 89C-94C
17. Fluvastatin. DRUGDEX System [intranet database]. Version 5.1 (2007), Thompson Healthcare, Greenwood Village, CO
18. Rosuvastatin. DRUGDEX System [intranet database]. Version 5.1 (2007), Thomson Healthcare, Greenwood Village, CO
19. Bellosta S., Paoletti R., and Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 109 suppl III (2004) III-50-III-57
20. Pravastatin [product monograph] (2007), Bristol-Myers Squibb Company, Princeton, NJ
21. Lovastatin [product monograph] (2007), Merck & Co, Whitehouse Station, NJ
22. Rosuvastatin [product monograph] (2007), AstraZeneca, Wilmington, DE
23. Belay B., Belamarich P.F., and Tom-Revzon C. The use of statins in pediatrics: knowledge base, limitations and future directions. Pediatrics 119 (2007) 370-380
24. Gotto Jr. A.M. Targeting high-risk young patients for statin therapy. JAMA 292 (2004) 377-378
25. Rifkind B.M., Schucker B., and Gordon D.J. When should patients with heterozygous familial hypercholesterolemia be treated?. JAMA 281 (1999) 180-181
26. Kosoglou T., Kakkar T., Statkevich P., et al. Multiple-dose safety and pharmacokinetics of ezetimibe in adolescent children. Clin Pharmacol Ther 69 (2001) P52
27. Salen G., Starc T., McCrary Sisk C.M., and Patel S.B. Intestinal cholesterol inhibitor ezetimibe added to cholestyramine for sitosterolermia and xanthomatosis. Gastroenterology 130 (2006) 1853-1857
28. Lind S., Olsson A.G., Eriksson M., Rudling M., Eggertsen G., and Angelin B. Autosomal recessive hypercholesterolaemia: normalization of plasma LDL cholesterol by ezetimibe in combination with statin treatment. J Intern Med 256 (2004) 406-412
29. Rodenburg J., Wiegman A., Vissers M.N., Kastelein J.J., and Stalenhoef A.F. A boy with autosomal recessive hypercholesterolaemia. Neth J Med 62 (2004) 89-93
30. The Pravastatin Multicenter Study Group II. Comparative efficacy and safety of pravastatin and cholestyramine alone and combined in patients with hypercholesterolemia. Arch Intern Med 153 (1993) 1321-1329
31. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 251 (1984) 351-364
32. Davidson M.H., Dillon M.A., Gordon B., et al. Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch Intern Med 159 (1999) 1893-1900
33. Insull Jr. W., Toth P., Mullican W., et al. Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial. Mayo Clin Proc 76 (2001) 971-982
34. Lees R.S., and Wilson D.E. The treatment of hyperlipidemia. N Engl J Med 284 (1971) 186-195
35. Mandeville W.H., and Arbeeny C. Bile acid sequestrants: their use in combination with other lipid-lowering agents. Drugs 2 (1999) 237-242
36. Tonstad S., Knudtzon J., Sivertsen M., Refsum H., and Ose L. Efficacy and safety of cholestyramine therapy in peripubertal and prepubertal children with familial hypercholesterolemia. J Pediatr 129 (1996) 42-49
37. McCrindle B.W., O'Neill M.B., Cullen-Dean G., and Helden E. Acceptability and compliance with two forms of cholestyramine in the treatment of hypercholesterolemia in children: a randomized, crossover trial. J Pediatr 130 (1997) 266-273
38. Tonstad S., and Ose L. Colestipol tablets in adolescents with familial hypercholesterolemia. Acta Paediatr 85 (1996) 1080-1082
39. National Institutes of Health. Efficacy and safety of colesevelam in pediatric patients with genetic high cholesterol. http://www.clinicaltrials.gov/ct/show/NCT00355615 Accessed December 2007
40. Levy R.I., and Rifkind B.M. Lipid lowering drugs and hyperlipidemia. Drugs 6 (1973) 12-45
41. Drug evaluation: Colesevelam. In: Gelman C.R., and Rumack B.H. (Eds). DRUGDEX Information System (2008), MICROMEDEX, Inc, Denver, CO
42. Leonard J.P., Desager J.P., Beckers C., and Harvengt C. In vitro binding of various biological substances by two hypocholesterolaemic resins, cholestyramine and colestipol. Arzneimittelforschung 29 (1979) 979-981
43. Altschul R., Hoffer A., and Stephen J.D. Influence of nicotinic acid on serum cholesterol in man. Arch Biochem 54 (1955) 558-559
44. Knopp R.H., Ginsberg J., Albers J.J., et al. Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin. Metabolism 34 (1985) 642-650
45. Grundy S.M., Mok H.Y.I., Zech L., and Berman M. Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man. J Lipid Res 22 (1981) 24-36
46. Kastelein J.J. Modifying plasma low-density lipoprotein and high-density lipoprotein cholesterol: what combinations are available in the future?. Am J Cardiol 96 9A (2005) 20K-27K
47. Knopp R.H., Alagona P., Davidson M., et al. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night vs. plain niacin in the management of hyperlipidemia. Metabolism 47 (1998) 1097-1104
48. Colletti R.B., Neufeld E.J., Roff N.K., McAuliffe T.L., Baker A.L., and Newburger J.W. Niacin treatment of hypercholesterolemia in children. Pediatrics 92 (1993) 78-82
49. Harper C.R., and Jacobson T.A. New perspectives on the management of low levels of high-density lipoprotein cholesterol. Arch Intern Med 159 (1999) 1049-1057
50. McKenney J.M., Proctor J.D., Harris S., and Chinchili V.M. A comparison of the efficacy and toxic effects of sustained- vs. immediate-release niacin in hypercholesterolemic patients. JAMA 271 (1994) 672-677
51. Drug evaluation: Niacin (Niaspan) Product info. In: Gelman C.R., and Rumack B.H. (Eds). DRUGDEX Information System (2008), MICROMEDEX, Inc, Denver, CO
52. Garg A., and Grundy S.M. Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. JAMA 264 (1990) 723-726
53. Crouse III J.R. New developments in the use of niacin for treatment of hyperlipidemia: new considerations in the use of an old drug. Coron Artery Dis 7 (1996) 321-326
54. Brunzell J.D., and Bierman E.L. Chylomicronemia syndrome. Interaction of genetic and acquired hypertriglyceridemia. Med Clin North Am 66 (1982) 455-468
55. Knopp R.H., Brown W.V., Dujovne C.A., et al. Effects of fenofibrate on plasma lipoproteins in hypercholesterolemia and combined hyperlipidemia. Am J Med 83 suppl 5B (1987) 50-59
56. Auwerx J., Schoonjams K., Fruchart J.C., and Staels B. Transcriptional control of triglyceride metabolism: fibrates and fatty acids change the expression of the LPL and apo C-III genes by activating the nuclear receptor PPAR. Atherosclerosis 124 suppl (1996) S29-S37
57. Staels B., Dallongeville J., Auwerx J., Schoonjans K., Leitersdorf E., and Fruchart J.C. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98 (1998) 2088-2093
58. Steinmetz J., Morin C., Panek E., Siest G., and Drouin P. Biological variations in hyperlipidemic children and adolescents treated with fenofibrate. Clin Chima Acta 112 (1981) 43-53
59. Chicaud P., Demange J., Drouin P., and Debry G. Action of fenofibrate in hypercholesterolemic children. 18-month followup. Presse Med 13 (1984) 417-419
60. Smalley C. Treatment of severe metabolic syndrome with gemfibrozil in a pediatric population. Presented at 2007 American College of Cardiology 56th Annual Scientific Session. Abstract 1005-27.
61. van Puijenbroek E.P., Du Buf-Vereijken P.W.G., Spooren P.F., and van Doormaal J.J. Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil. J Intern Med 240 (1996) 403-404
62. East C., Alivizatos P.A., Grundy S.M., Jones P.H., and Farmer J.A. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation+. N Engl J Med 318 (1988) 47-48
63. Schonfield G. The effects of fibrates on lipoprotein and hemostatic coronary risk factors. Athersclerosis 111 (1994) 161-174
64. The Coronary Drug Project Research Group. Gallbladder disease as a side effect of drugs influencing lipid metabolism. Experience in the Coronary Drug Project. N Engl J Med 296 (1977) 1185-1190
65. American Diabetes Association. Management of dyslipidemia in children and adolescents with diabetes. Diabetes Care 26 (2003) 2194-2197
66. Balfour J.A., McTavish D., and Heel R.C. Fenofibrate: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidemia. Drugs 40 (1990) 260-290
67. Kris-Etherton P.M., Harris W.S., Appel L.J., American Heart Association, and Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 106 (2002) 2747-2757
68. Drug evaluation: Omega-3-acid ethyl esters (Lovaza) Product info. In: Gelman C.R., and Rumack B.H. (Eds). DRUGDEX Information System (2008), MICROMEDEX, Inc, Denver, CO
69. Harris W.S., Ginsberg H.N., Arunakul N., et al. Safety and efficacy of Omacor in severe hypertriglyceridemia. J Cardiovasc Risk 4 (1997) 385-391
70. Donadio Jr. J.V., Larson T.S., Bergstralh E.J., and Grande J.P. A randomized trial of high-dose compared with low-dose omega-3 fatty acids in severe IgA nephropathy. J Am Soc Nephrol 12 (2001) 791-799
71. Engler M.M., Engler M.B., Malloy M.J., Paul S.M., Kulkarni K.R., and Mietus-Snyder M.L. Effect of docosahexaenoic acid on lipoprotein subclasses in hyperlipidemic children (the EARLY study). Am J Cardiol 95 (2005) 869-871
72. Clarke J.T., Cullen-Dean G., Regelink E., Chan L., and Rose V. Increased incidence of epistaxis in adolescents with familial hypercholesterolemia treated with fish oil. Clin Lab Observ 116 (1989) 139-141
73. Bays H.E. Safety considerations with omega-3 fatty acid therapy. Am J Cardiol 99 suppl (2007) 35C-43C
74. Sampath H., and Ntambi J.M. Polyunsaturated fatty acid regulation of gene expression. Nutr Rev 62 (2004) 333-339
75. Bezard J., Blond J.P., Bernard A., and Clouet P. The metabolism and availability of essential fatty acids in animal and human tissues. Reprod Nutr Dev 34 (1994) 539-568
76. Devaney B., Ziegler P., Pac S., Karwe V., and Barr S.I. Nutrient intakes of infants and toddlers. J Am Diet Assoc 104 Suppl (2004) 14-21